Skip to main content

Table 4 Serum concentration of TSLP in control and Graves’ disease patients

From: Thymic stromal lymphopoietin gene promoter polymorphisms and expression levels in Graves’ disease and Graves’ ophthalmopathy

Samples

No.

TSLP concentration (pg/ml)

P a

P b

Control

272

15.46 ± 35.25

  

GD

432

109.93 ± 189.13

< 0.00001

 

GD/GO

184

113.43 ± 221.44

< 0.00001

 

GD/w/o GO

248

107.33 ± 161.47

< 0.00001

0.75

Female

    

Control

166

17.90 ± 29.69

  

GD

343

111.70 ± 189.30

< 0.00001

 

GD/GO

138

114.55 ± 216.48

< 0.00001

 

GD/w/o GO

205

109.77 ± 169.10

< 0.00001

0.83

Male

    

Control

106

11.64 ± 43.96

  

GD

89

103.11 ± 189.38

< 0.00001

 

GD/GO

46

110.06 ± 238.15

< 0.00001

 

GD/w/o GO

43

95.68 ± 119.46

< 0.00001

0.72

  1. a P values were determined by unpaired T test to compare between control and GD, GD/GO, GD/w/o GO. b P values were determined by unpaired T test to compare between GD/GO and GD/w/o GO. P values less than 0.05 were considered significant.